Metabolic and immunological assessment of small-for-gestational-age children during one-year treatment with growth hormone

The clinical impact of apolipoproteins

Kanako Kojima-Ishii, Naoko Toda, Kazuhiro Okubo, Vlad Tocan, Noriko Ohyama, Mika Makimura, Terumichi Matsuo, Masayuki Ochiai, Shoichi Ohga, Kenji Ihara

Research output: Contribution to journalArticle

Abstract

Children born small for gestational age (SGA) are at a higher risk for metabolic disorders later in life. In this study, we aimed to characterize young SGA children without catch-up growth and evaluate the effects of GH treatment on endocrinological, metabolic, and immunological parameters. Study design is a one-year single hospital-based study included prospective observation of SGA patients during 12 months of GH treatment. Clinical and laboratory profiles of SGA children at baseline were compared with controls born appropriate size for age. Twenty-six SGA children (median age, 3.4 years) and 26 control children (median age, 3.8 years) were enrolled. Anthropometric, hematologic, biochemical, immunological, and endocrinological parameters were assessed at baseline and 1, 3, 6, 9, and 12 months after the start of GH treatment. As a result, median height SD score (SDS) of SGA children increased by +0.42 with 12-month GH treatment. Body mass index SDS was lower in SGA children than in controls. Serum apolipoprotein A1 increased, whereas apolipoprotein B decreased during GH treatment. Serum leptin and resistin levels, which were lower in SGA children than in controls at baseline, did not change remarkably with GH treatment. Monocyte counts, which were lower in SGA patients at baseline, increased after GH treatment. Neutrophil counts significantly increased after GH treatment. Natural killer cell ratios, which were higher in SGA patients, decreased after GH treatment. In conclusion, there was no evidence suggesting metabolic abnormalities in SGA children. Serum apolipoprotein changes might predict the beneficial role of GH treatment in lowering cardiometabolic risk.

Original languageEnglish
Pages (from-to)449-459
Number of pages11
JournalEndocrine Journal
Volume65
Issue number4
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Apolipoproteins
Growth Hormone
Gestational Age
Therapeutics
Serum
Resistin
Apolipoprotein A-I
Apolipoproteins B
Leptin
Natural Killer Cells
Monocytes
Body Mass Index
Neutrophils
Observation
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Metabolic and immunological assessment of small-for-gestational-age children during one-year treatment with growth hormone : The clinical impact of apolipoproteins. / Kojima-Ishii, Kanako; Toda, Naoko; Okubo, Kazuhiro; Tocan, Vlad; Ohyama, Noriko; Makimura, Mika; Matsuo, Terumichi; Ochiai, Masayuki; Ohga, Shoichi; Ihara, Kenji.

In: Endocrine Journal, Vol. 65, No. 4, 01.01.2018, p. 449-459.

Research output: Contribution to journalArticle

Kojima-Ishii, Kanako ; Toda, Naoko ; Okubo, Kazuhiro ; Tocan, Vlad ; Ohyama, Noriko ; Makimura, Mika ; Matsuo, Terumichi ; Ochiai, Masayuki ; Ohga, Shoichi ; Ihara, Kenji. / Metabolic and immunological assessment of small-for-gestational-age children during one-year treatment with growth hormone : The clinical impact of apolipoproteins. In: Endocrine Journal. 2018 ; Vol. 65, No. 4. pp. 449-459.
@article{3a5097db274f4a04910002df33809a6b,
title = "Metabolic and immunological assessment of small-for-gestational-age children during one-year treatment with growth hormone: The clinical impact of apolipoproteins",
abstract = "Children born small for gestational age (SGA) are at a higher risk for metabolic disorders later in life. In this study, we aimed to characterize young SGA children without catch-up growth and evaluate the effects of GH treatment on endocrinological, metabolic, and immunological parameters. Study design is a one-year single hospital-based study included prospective observation of SGA patients during 12 months of GH treatment. Clinical and laboratory profiles of SGA children at baseline were compared with controls born appropriate size for age. Twenty-six SGA children (median age, 3.4 years) and 26 control children (median age, 3.8 years) were enrolled. Anthropometric, hematologic, biochemical, immunological, and endocrinological parameters were assessed at baseline and 1, 3, 6, 9, and 12 months after the start of GH treatment. As a result, median height SD score (SDS) of SGA children increased by +0.42 with 12-month GH treatment. Body mass index SDS was lower in SGA children than in controls. Serum apolipoprotein A1 increased, whereas apolipoprotein B decreased during GH treatment. Serum leptin and resistin levels, which were lower in SGA children than in controls at baseline, did not change remarkably with GH treatment. Monocyte counts, which were lower in SGA patients at baseline, increased after GH treatment. Neutrophil counts significantly increased after GH treatment. Natural killer cell ratios, which were higher in SGA patients, decreased after GH treatment. In conclusion, there was no evidence suggesting metabolic abnormalities in SGA children. Serum apolipoprotein changes might predict the beneficial role of GH treatment in lowering cardiometabolic risk.",
author = "Kanako Kojima-Ishii and Naoko Toda and Kazuhiro Okubo and Vlad Tocan and Noriko Ohyama and Mika Makimura and Terumichi Matsuo and Masayuki Ochiai and Shoichi Ohga and Kenji Ihara",
year = "2018",
month = "1",
day = "1",
doi = "10.1507/endocrj.EJ17-0485",
language = "English",
volume = "65",
pages = "449--459",
journal = "Endocrine Journal",
issn = "0918-8959",
publisher = "Japan Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Metabolic and immunological assessment of small-for-gestational-age children during one-year treatment with growth hormone

T2 - The clinical impact of apolipoproteins

AU - Kojima-Ishii, Kanako

AU - Toda, Naoko

AU - Okubo, Kazuhiro

AU - Tocan, Vlad

AU - Ohyama, Noriko

AU - Makimura, Mika

AU - Matsuo, Terumichi

AU - Ochiai, Masayuki

AU - Ohga, Shoichi

AU - Ihara, Kenji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Children born small for gestational age (SGA) are at a higher risk for metabolic disorders later in life. In this study, we aimed to characterize young SGA children without catch-up growth and evaluate the effects of GH treatment on endocrinological, metabolic, and immunological parameters. Study design is a one-year single hospital-based study included prospective observation of SGA patients during 12 months of GH treatment. Clinical and laboratory profiles of SGA children at baseline were compared with controls born appropriate size for age. Twenty-six SGA children (median age, 3.4 years) and 26 control children (median age, 3.8 years) were enrolled. Anthropometric, hematologic, biochemical, immunological, and endocrinological parameters were assessed at baseline and 1, 3, 6, 9, and 12 months after the start of GH treatment. As a result, median height SD score (SDS) of SGA children increased by +0.42 with 12-month GH treatment. Body mass index SDS was lower in SGA children than in controls. Serum apolipoprotein A1 increased, whereas apolipoprotein B decreased during GH treatment. Serum leptin and resistin levels, which were lower in SGA children than in controls at baseline, did not change remarkably with GH treatment. Monocyte counts, which were lower in SGA patients at baseline, increased after GH treatment. Neutrophil counts significantly increased after GH treatment. Natural killer cell ratios, which were higher in SGA patients, decreased after GH treatment. In conclusion, there was no evidence suggesting metabolic abnormalities in SGA children. Serum apolipoprotein changes might predict the beneficial role of GH treatment in lowering cardiometabolic risk.

AB - Children born small for gestational age (SGA) are at a higher risk for metabolic disorders later in life. In this study, we aimed to characterize young SGA children without catch-up growth and evaluate the effects of GH treatment on endocrinological, metabolic, and immunological parameters. Study design is a one-year single hospital-based study included prospective observation of SGA patients during 12 months of GH treatment. Clinical and laboratory profiles of SGA children at baseline were compared with controls born appropriate size for age. Twenty-six SGA children (median age, 3.4 years) and 26 control children (median age, 3.8 years) were enrolled. Anthropometric, hematologic, biochemical, immunological, and endocrinological parameters were assessed at baseline and 1, 3, 6, 9, and 12 months after the start of GH treatment. As a result, median height SD score (SDS) of SGA children increased by +0.42 with 12-month GH treatment. Body mass index SDS was lower in SGA children than in controls. Serum apolipoprotein A1 increased, whereas apolipoprotein B decreased during GH treatment. Serum leptin and resistin levels, which were lower in SGA children than in controls at baseline, did not change remarkably with GH treatment. Monocyte counts, which were lower in SGA patients at baseline, increased after GH treatment. Neutrophil counts significantly increased after GH treatment. Natural killer cell ratios, which were higher in SGA patients, decreased after GH treatment. In conclusion, there was no evidence suggesting metabolic abnormalities in SGA children. Serum apolipoprotein changes might predict the beneficial role of GH treatment in lowering cardiometabolic risk.

UR - http://www.scopus.com/inward/record.url?scp=85045961070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045961070&partnerID=8YFLogxK

U2 - 10.1507/endocrj.EJ17-0485

DO - 10.1507/endocrj.EJ17-0485

M3 - Article

VL - 65

SP - 449

EP - 459

JO - Endocrine Journal

JF - Endocrine Journal

SN - 0918-8959

IS - 4

ER -